A. M. M. Eggermont

1.1k total citations
25 papers, 919 citations indexed

About

A. M. M. Eggermont is a scholar working on Oncology, Immunology and Genetics. According to data from OpenAlex, A. M. M. Eggermont has authored 25 papers receiving a total of 919 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Immunology and 5 papers in Genetics. Recurrent topics in A. M. M. Eggermont's work include Hepatocellular Carcinoma Treatment and Prognosis (5 papers), Immunotherapy and Immune Responses (4 papers) and Cutaneous Melanoma Detection and Management (4 papers). A. M. M. Eggermont is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (5 papers), Immunotherapy and Immune Responses (4 papers) and Cutaneous Melanoma Detection and Management (4 papers). A. M. M. Eggermont collaborates with scholars based in Netherlands, United Kingdom and Switzerland. A. M. M. Eggermont's co-authors include Paul H. Sugarbaker, Anne E. M. van der Pool, Johannes H.W. de Wilt, Jan N.M. IJzermans, C. Verhoef, Ronald Damhuis, Ries Kranse, F. Lejeune, Nathalie Renard and Laurence Lespagnard and has published in prestigious journals such as British Journal of Cancer, Annals of Oncology and International Journal of Cancer.

In The Last Decade

A. M. M. Eggermont

25 papers receiving 899 citations

Peers

Countries citing papers authored by A. M. M. Eggermont

Since Specialization

Citations

This map shows the geographic impact of A. M. M. Eggermont's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. M. M. Eggermont with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. M. M. Eggermont more than expected).

Fields of papers citing papers by A. M. M. Eggermont

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. M. M. Eggermont. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. M. M. Eggermont. The network helps show where A. M. M. Eggermont may publish in the future.

Co-authorship network of co-authors of A. M. M. Eggermont

This figure shows the co-authorship network connecting the top 25 collaborators of A. M. M. Eggermont. A scholar is included among the top collaborators of A. M. M. Eggermont based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. M. M. Eggermont. A. M. M. Eggermont is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PCN378 - MINIMALLY IMPORTANT DIFFERENCES FOR INTERPRETING EORTC QLQ-C30 SCORES IN MELANOMA, BREAST CANCER AND HEAD AND NECK CANCER PATIENTS ON BEHALF OF THE EORTC BREAST, HEAD AND NECK, MELANOMA AND QUALITY OF LIFE GROUPS 2018 ·Value in Health ·(unknown), Corneel Coens, Frédéric Fiteni, Katarzyna Pogoda, Fátima Cardoso, Silke Tribius, Susanne Singer, Sjoukje F. Oosting, Nicola S. Russell, Christian Simon, (unknown), V. Grégoire, Galina Velikova, Madeleine King, Mogens Grønvold, Kim Cocks, Mirjam A. G. Sprangers, A. M. M. Eggermont, Yvonne Brandberg, Andrew Bottomley	1
2	Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population‐based series 2010 ·Colorectal Disease ·Anne E. M. van der Pool, Ronald Damhuis, Jan N.M. IJzermans, Johannes H.W. de Wilt, A. M. M. Eggermont, Ries Kranse, C. Verhoef	184
3	‘Staged’ liver resection in synchronous and metachronous colorectal hepatic metastases: differences in clinicopathological features and outcome 2009 ·Colorectal Disease ·Anne E. M. van der Pool, Zarina S. Lalmahomed, (unknown), Johannes H.W. de Wilt, A. M. M. Eggermont, (unknown), Cornelis Verhoef	32
4	Population-based survival of melanoma: much better survival rates than estimated by the AJCC 2006 ·Melanoma Research ·Elisabeth G.E. de Vries, Saskia Houterman, Tamar Nijsten, Marcus L.F. Janssen, A. M. M. Eggermont, J.W.W. Coebergh	2
5	Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity 2002 ·British Journal of Cancer ·Ann L.B. Seynhaeve, Johannes H. W. de Wilt, Sandra T. van Tiel, A. M. M. Eggermont, Timo L.M. ten Hagen	2
6	Synergistic antitumour effect of TNF-SAM2 with melphalan and doxorubicin in isolated limb perfusion in rats. 2001 ·PubMed ·Johannes H. W. de Wilt, (unknown), Timo L.M. ten Hagen, (unknown), Koichi Takagi, Peet Nooijen, Ann L.B. Seynhaeve, A. M. M. Eggermont	6
7	Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats 1999 ·British Journal of Cancer ·Johannes H. W. de Wilt, Eric R. Manusama, Sandra T. van Tiel, Marc G. A. van Ijken, Timo L.M. ten Hagen, A. M. M. Eggermont	2
8	Isolated Hepatic Perfusion with Tumor Necrosis Factor α and Melphalan: Experimental Studies in Pigs and Phase I Data from Humans 1998 ·Recent results in cancer research ·Mark R. de Vries, Inne H. Borel Rinkes, (unknown), Th. Wiggers, Robert A.E.M. Tollenaar, Peter J.K. Kuppen, Alexander L. Vahrmeijer, A. M. M. Eggermont	48
9	Liver and tumour tissue concentrations of TNF-alpha in cancer patients treated with TNF-alpha and melphalan by isolated liver perfusion 1997 ·British Journal of Cancer ·Peter J.K. Kuppen, (unknown), (unknown), (unknown), (unknown), IHM Borel Rinkes, A. M. M. Eggermont	15
10	Prolonged continuous hepatic artery infusion with interleukin-2 in unresectable liver metastases of colorectal cancer: A phase IA—B study 1996 ·Annals of Oncology ·S.H. Goey, A. M. M. Eggermont, R. Oskam, Th. Wiggers, R. L. H. Bolhuis, G. Stoter	2
11	Synergistic effects of TNF-α and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study 1996 ·British Journal of Cancer ·(unknown), (unknown), A. M. M. Eggermont, Lia Schalkwijk, (unknown), R. L. Marquet, (unknown), (unknown)	73
12	Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. 1996 ·PubMed ·W. Martin C. Klop, B. C. Vrouenraets, Bert N. van Geel, A. M. M. Eggermont, Joost M. Klaase, Omgo E. Nieweg, B.B.R. Kroon	27
13	Transforming growth factor beta secretion from primary breast cancer fibroblasts 1995 ·Molecular and Cellular Endocrinology ·(unknown), J.G.M. Klijn, B van Ooijen, (unknown), A. M. M. Eggermont, S.C. Henzen‐Logmans, John A. Foekens	35
14	Harly endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high‐dose tumour necrosis factor alpha (rTNFα) 1994 ·International Journal of Cancer ·Nathalie Renard, D. Liénard, Laurence Lespagnard, A. M. M. Eggermont, R Heimann, F. Lejeune	127
15	Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. 1994 ·PubMed ·Joost M. Klaase, B.B.R. Kroon, (unknown), A. M. M. Eggermont, H. R. Franklin, A. A. M. Hart	84
16	Regional application of cytokines: Experience with various clinical protocols 1992 ·Pharmacological Research ·A. M. M. Eggermont, S.H. Goey, R. L. H. Bolhuis, G. Stoter	1
17	Stromal influences on breast cancer cell growth 1992 ·British Journal of Cancer ·(unknown), B van Ooijen, J.G.M. Klijn, (unknown), A. M. M. Eggermont, S.C. Henzen‐Logmans, (unknown)	76
18	Solitary malignant Schwannoma: clinical aspects, immunohistochemistry and ultrastructure. 1990 ·PubMed ·Koert P. de Jong, (unknown), A. M. M. Eggermont, J Jeekel	4
19	Reconstruction of chest wall defects with homologous dura mater grafts 1989 ·British journal of surgery ·A.N. van Geel, Theo Wiggers, A. M. M. Eggermont	4
20	Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effects of interleukin-2 and lymphokine-activated killer cells. 1987 ·PubMed ·A. M. M. Eggermont, (unknown), Paul H. Sugarbaker	179

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact